Donor immune cells take on tough leukemia in early trial
NCT ID NCT06326008
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a two-step approach for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. First, patients receive donor-derived CD19 CAR T cells, then a stem cell transplant from the same donor, followed by donor-derived CD22 CAR T cells. The goal is to see if this combination is safe and tolerable. About 48 participants will be enrolled to assess side effects and begin to look at how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- donor-derived CD19 and CD22 CAR T cells
- What this could lead to
- If successful, this could offer a new treatment option for patients with hard-to-treat B-cell acute lymphoblastic leukemia who have run out of standard therapies.
- What could go wrong
- This is a very early phase 1 trial with only 48 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects from the CAR T cells and stem cell transplant, including graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells be engineered to fight blood cancer?
- Can we make CAR-T cells last longer in leukemia?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Personalized chemo dosing may boost leukemia remission in kids
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot